231 related articles for article (PubMed ID: 34367174)
1. Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation.
Mishra HK; Dixon KJ; Pore N; Felices M; Miller JS; Walcheck B
Front Immunol; 2021; 12():711621. PubMed ID: 34367174
[TBL] [Abstract][Full Text] [Related]
2. Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils.
Snyder KM; McAloney CA; Montel JS; Modiano JF; Walcheck B
Vet Immunol Immunopathol; 2021 Jan; 231():110162. PubMed ID: 33264689
[TBL] [Abstract][Full Text] [Related]
3. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.
Mishra HK; Pore N; Michelotti EF; Walcheck B
Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334
[TBL] [Abstract][Full Text] [Related]
4. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
Wu J; Mishra HK; Walcheck B
J Leukoc Biol; 2019 Jun; 105(6):1297-1303. PubMed ID: 30786043
[TBL] [Abstract][Full Text] [Related]
5. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).
Romee R; Foley B; Lenvik T; Wang Y; Zhang B; Ankarlo D; Luo X; Cooley S; Verneris M; Walcheck B; Miller J
Blood; 2013 May; 121(18):3599-608. PubMed ID: 23487023
[TBL] [Abstract][Full Text] [Related]
6. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
7. ADAM17 protects against elastase-induced emphysema by suppressing CD62L
Suzuki S; Ishii M; Asakura T; Namkoong H; Okamori S; Yagi K; Kamata H; Kusumoto T; Kagawa S; Hegab AE; Yoda M; Horiuchi K; Hasegawa N; Betsuyaku T
Am J Physiol Lung Cell Mol Physiol; 2020 Jun; 318(6):L1172-L1182. PubMed ID: 32130031
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
10. The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell's function.
Shi Y; Pan J; Hang C; Tan L; Hu L; Yan Z; Zhu J
Environ Toxicol; 2023 Jul; 38(7):1618-1627. PubMed ID: 37052432
[TBL] [Abstract][Full Text] [Related]
11. Effect of Interleukin-15 on CD11b, CD54, and CD62L Expression on Natural Killer Cell and Natural Killer T-Like Cells in Systemic Lupus Erythematosus.
Lin SJ; Chen JY; Kuo ML; Hsiao HS; Lee PT; Huang JL
Mediators Inflamm; 2016; 2016():9675861. PubMed ID: 27847409
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Front Immunol; 2019; 10():1262. PubMed ID: 31231387
[TBL] [Abstract][Full Text] [Related]
14. The role of ADAM17 in the T-cell response against bacterial pathogens.
Link MA; Lücke K; Schmid J; Schumacher V; Eden T; Rose-John S; Mittrücker HW
PLoS One; 2017; 12(9):e0184320. PubMed ID: 28877252
[TBL] [Abstract][Full Text] [Related]
15. A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis.
Mudter J; Wirtz S; Galle PR; Neurath MF
Pathobiology; 2002-2003; 70(3):170-6. PubMed ID: 12571422
[TBL] [Abstract][Full Text] [Related]
16. TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity.
Kaminski MF; Bendzick L; Hopps R; Kauffman M; Kodal B; Soignier Y; Hinderlie P; Walker JT; Lenvik TR; Geller MA; Miller JS; Felices M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36162918
[TBL] [Abstract][Full Text] [Related]
17. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Blood; 2016 Sep; 128(11):1475-89. PubMed ID: 27465917
[TBL] [Abstract][Full Text] [Related]
18. ADAM17 controls IL-6 signaling by cleavage of the murine IL-6Rα from the cell surface of leukocytes during inflammatory responses.
Yan I; Schwarz J; Lücke K; Schumacher N; Schumacher V; Schmidt S; Rabe B; Saftig P; Donners M; Rose-John S; Mittrücker HW; Chalaris A
J Leukoc Biol; 2016 May; 99(5):749-60. PubMed ID: 26561568
[TBL] [Abstract][Full Text] [Related]
19. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.
Wagner JA; Rosario M; Romee R; Berrien-Elliott MM; Schneider SE; Leong JW; Sullivan RP; Jewell BA; Becker-Hapak M; Schappe T; Abdel-Latif S; Ireland AR; Jaishankar D; King JA; Vij R; Clement D; Goodridge J; Malmberg KJ; Wong HC; Fehniger TA
J Clin Invest; 2017 Nov; 127(11):4042-4058. PubMed ID: 28972539
[TBL] [Abstract][Full Text] [Related]
20. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
